Pinnacle Wealth Planning Services’s Neurocrine Biosciences NBIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$7.8K Buy
55
+2
+4% +$321 ﹤0.01% 2176
2026
Q2
$8.93K Buy
53
+2
+4% +$297 ﹤0.01% 2112
2026
Q1
$6.72K Buy
51
+3
+6% +$398 ﹤0.01% 2163
2025
Q4
$6.81K Buy
+48
New +$6.95K ﹤0.01% 2179
2021
Q1
– Sell
-26
Closed -$2K – 1366
2020
Q4
$2K Buy
+26
New +$2.51K ﹤0.01% 1953

Other funds holding NBIX

Pinnacle Wealth Planning Services's NBIX Position: Q3 2026 in Review

Pinnacle Wealth Planning Services increased its Neurocrine Biosciences (NBIX) stake by 3.8% in Q3 2026, buying an estimated $321 and bringing the position to 55 shares worth $7.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2176.

Pinnacle Wealth Planning Services first reported a position in NBIX in Q4 2020 and has held it in 5 quarters since. The position peaked at $8.93K in Q2 2026. 773 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • Pinnacle Wealth Planning Services held 55 shares of Neurocrine Biosciences worth $7.8K as of Q3 2026.
  • Pinnacle Wealth Planning Services bought 2 Neurocrine Biosciences shares in Q3 2026, an estimated $321.
  • Neurocrine Biosciences made up ﹤0.01% of Pinnacle Wealth Planning Services's portfolio in Q3 2026, its #2176 holding.
  • Pinnacle Wealth Planning Services first reported a position in Neurocrine Biosciences in Q4 2020 and has held it in 5 quarters since.
  • Pinnacle Wealth Planning Services's Neurocrine Biosciences position peaked at $8.93K in Q2 2026.
  • 773 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Pinnacle Wealth Planning Services's 13F filing for Q3 2026, filed 27 Oct 2026.